# US 2018/0023078 A1 · Oligonucleotide Sequences Targeting Transcription FactorTSC22D4 for the Treatment of Insulin Resistance

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0023078 A1
- Document ID: US20180023078A1
- Status: Published application
- Kind: A1
- Application number: 15/545,104
- Filed: 2016-02-12
- Published: 2018-01-25
- Earliest claimed: 2015-03-23
- Assignees: Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
- Applicants: Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
- Inventors: Stephan HERZIG; Mauricio BARRIEL DIAZ; Tobias SCHAFMEIER
- Web page: https://patentgrep.com/patent/US20180023078A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/3181: Peptide nucleic acid, PNA
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to oligonucleotide inhibitors of the TSC22D4 activity or expression and their uses for the prevention, treatment, and/or regulation of insulin resistance, metabolic syndrome and/or diabetes and/or for improving insulin sensitivity in a mammal.

## Claims

### Claim 1

An inhibitor of the-expression and/or biological activity of TSC22D4 wherein said inhibitor is selected from an oligonucleotide that is an interfering ribonucleic acid, PNA (protein nucleic acid) or LNA (locked nucleic acid), and wherein said oligonucleotide comprises at least one sequence selected from:
5′-GGACGUGUGUGGAUGUUUAdTdT-3′ (SEQ ID NO: 1);
5′-GGAUGUUUACGAGAGAGAUdTdT-3′ (SEQ ID NO: 2);
5′-AGUCCCACCUCAUGUUUGCdTdT-3′ (SEQ ID NO: 3);
antisense sequences thereof, and functional variants thereof.

### Claim 2 (depends on 1)

The inhibitor according to claim 1, wherein the interfering ribonucleic acid is a small interfering ribonucleic acid (siRNA) or small hairpin ribonucleic acid (shRNA) or micro ribonucleic acid (miRNA) or a combination thereof.

### Claim 3 (depends on 1)

The inhibitor according to claim 1, wherein the siRNA has a length of between 19 to 30 nucleotides.

### Claim 4 (depends on 1)

The inhibitor according to claim 1, wherein the siRNA consists of at least one of SEQ ID NOs: 1 to 3.

### Claim 5 (depends on 1)

The inhibitor according to claim 1, wherein the functional variants thereof comprise at least one modified or substituted nucleotide.

### Claim 6 (depends on 1)

A recombinant vector, comprising an oligonucleotide according to claim 1.

### Claim 7 (depends on 1)

A recombinant cell, comprising an oligonucleotide according to claim 1.

### Claim 8 (depends on 1)

A pharmaceutical composition, comprising at least one of the inhibitor according to claim 1, together with a pharmaceutically acceptable carrier.

### Claim 9 (depends on 8)

The pharmaceutical composition according to claim 8, wherein said pharmaceutical composition is formulated for administration orally, rectally, transmucosally, transdermally, intestinally, parenterally, intramuscularly, intrathecally, direct intraventricularly, intravenously, intraperitoneally, intranasally, intraocularly, or subcutaneously.

### Claim 10 (depends on 1)

The A method for prevention, regulation, and/or treatment of a disease, and/or for improving insulin sensitivity, wherein said method comprises administering, to a subject in need of such prevention, regulation, treatment, and/or improvement, the inhibitor according to claim 1.

### Claim 11 (depends on 10)

The method, according to claim 10, wherein said disease is selected from insulin resistance, hypertension, dyslipidemia, coronary artery disease, metabolic syndrome and diabetes type 1 or.

### Claim 12 (depends on 10)

The method, according to claim 10, wherein the insulin resistance is diet-induced insulin resistance and/or obesity-induced insulin resistance.

### Claim 13 (depends on 1)

A therapeutic kit, comprising the inhibitor according to claim 1, optionally together with suitable buffers and excipients, and instructions for use.

### Claim 14 (depends on 13)

The therapeutic kit according to claim 13 with instructions for use in the prevention, regulation, and/or treatment of a disease, wherein said disease is selected from insulin resistance, hypertension, dyslipidemia, coronary artery disease, metabolic syndrome and/or diabetes type 1 or 2, and/or for improving insulin sensitivity.

### Claim 15 (depends on 10)

The method, according to claim 10, for improving insulin sensitivity in the context of a tumorous disease.
